Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
Verified September 2014 by Massachusetts General Hospital
Information provided by (Responsible Party):
Gagan Joshi, MD, Massachusetts General Hospital
First received: March 24, 2014
Last updated: September 15, 2014
Last verified: September 2014
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning adults with autism spectrum disorders (ASD).
Autism Spectrum Disorder
Drug: Methylphenidate extended-release liquid formulation
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||November 2015 (Final data collection date for primary outcome measure)
Experimental: Methylphenidate extended-release liquid
Methylphenidate extended-release liquid formulation
Drug: Methylphenidate extended-release liquid formulation
- Methylphenidate extended-release liquid formulation
- Quillivant extended release
|Ages Eligible for Study:
||18 Years to 25 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male or female participants between 18 and 25 years of age (inclusive)
- Fulfills Diagnostic and Statistical Manual 5 (DSM-5) diagnostic criteria for autism spectrum disorder as established by the clinical diagnostic interview and Autism Diagnostic Observation Schedule (ADOS)
- Fulfills DSM-5 diagnostic criteria for Attention Deficit/Hyperactivity Disorder (ADHD) as established by the clinical diagnostic interview and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia-Epidemiological Version (K-SADS-E) ADHD module
- Participants with at least moderately severe symptoms of Autism Spectrum Disorder (ASD) as demonstrated by Social Responsiveness Scale (SRS) raw score greater than or equal to 85 and Clinical Global Impression (CGI)-ASD severity score greater than or equal to 4
- Participants with at least moderately severe symptoms of ADHD as assessed by AISRS score greater than or equal to 24 and CGI-ADHD severity score greater than or equal to 4
- Each participant must understand the nature of the study. The participant must sign an Institutional Review Board-approved informed consent form before initiation of any study procedures.
- Participant must have a level of understanding sufficient to communicate with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
- Participant must be able to participate in mandatory blood draws.
- Participant with major mood and/or anxiety disorders will be allowed to participate in the study provided they do not meet any exclusionary criteria.
- Impaired intellectual capacity (Intelligence Quotient [IQ] less than 85; one standard deviation below the mean IQ)
- Participant is unable to communicate due to delay in, or total lack of, spoken language development (grossly impaired language skills)
- Clinically unstable psychiatric conditions or judged to be at serious safety risk to self (suicidal risk) or others (within past 30 days).
- Current diagnosis (within past 30 days) of an anxiety, mood, or psychotic disorder.
- History of substance use (except nicotine or caffeine) within past 3 months (inclusive) or with urine drug screen positive for substances of abuse
- Subjects with a medical condition or treatment that will either jeopardize subject safety or affect the scientific merit of the study, including:
- Pregnant or nursing females or females with a positive urine pregnancy test.
- Uncorrected hypothyroidism or hyperthyroidism.
- History of non-febrile seizures within last 1 month without a clear and resolved etiology.
- History of renal or hepatic impairment.
- Serious, unstable systemic illness
- Personal history of cardiac disease or a family history of non-geriatric cardiac disease or death
- Clinically significant abnormal baseline laboratory values which include the following: Values more than 20% above the upper range of the laboratory standard for a basic metabolic screen.
- Systolic and diastolic blood pressure parameters above 140 and 90, respectively.
- Resting heart rate outside of 60-100 beats per minute.
- Abnormal electrocardiogram (ECG) parameters defined as a corrected QT interval greater than 460 milliseconds, QRS interval greater than 120 milliseconds, and/or PR interval greater than 200 milliseconds.
- ECG evidence of ischemia or arrhythmia as reviewed by an independent cardiologist.
- Participant with a history of non-response to adequate trial of methylphenidate (therapeutic dose for an adequate duration) as determined by clinician.
- History of intolerance or an allergic reaction to methylphenidate.
- Current treatment with first- or second-generation antipsychotic medications or stimulant class of anti-ADHD medications.
- Current treatment with monoamine oxidase inhibitors (MAOIs)
- Current treatment with a psychotropic medication on a dose that has not been stable for at least 4 weeks prior to baseline visit.
- Investigator and his/her immediate family, defined as the investigator's spouse, parent, child, grandparent, or grandchild.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02096952
Massachusetts General Hospital
||Gagan Joshi, MD
||Massachusetts General Hospital
No publications provided
||Gagan Joshi, MD, Assistant professor of Psychiatry, Harvard Medical School; Director, Autism Spectrum Disorder Clinical & Research Program, Pediatric Psychopharmacology, Massachusetts General Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 24, 2014
||September 15, 2014
||United States: Food and Drug Administration
Keywords provided by Massachusetts General Hospital:
Autism spectrum disorder
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 26, 2015
Attention Deficit Disorder with Hyperactivity
Child Development Disorders, Pervasive
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Nervous System Diseases
Signs and Symptoms
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs